ATAI:NASDAQ
AtaiBeckley Inc
US$4,50
arrow_downward
-0,66%(-0,030) 1 HR
US$4,49
arrow_downward
-0,22% (-0,010)bedtimeSetelah jam perdagangan normal
Tutup: 4 Jun, 16.00.01 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk ATAI...
Buka
US$4,50
Tinggi
US$4,74
Rendah
US$4,42
Kapitalisasi pasar
1,66 M
Volume rata-rata
4,85 jt
Volume
4,55 jt
Harga tinggi dalam 52 minggu terakhir
US$6,72
Harga rendah dalam 52 minggu terakhir
US$2,00
EPS
-US$2,23
Beta
1,60
Saham beredar
368,17 jt
Jumlah karyawan
99
Buka
US$4,50
Tinggi
US$4,74
Rendah
US$4,42
Kapitalisasi pasar
1,66 M
Volume rata-rata
4,85 jt
Volume
4,55 jt
Harga tinggi dalam 52 minggu terakhir
US$6,72
Harga rendah dalam 52 minggu terakhir
US$2,00
EPS
-US$2,23
Beta
1,60
Saham beredar
368,17 jt
Jumlah karyawan
99
Prospek analis
Rating Analis
Berdasarkan 11 analis yang memberikan rating saham untuk ATAI dalam 3 bulan terakhir
Sangat Disarankan Beli
Beli
11
Tahan
0
Jual
0
Perkiraan 12 bulan
Berdasarkan 11 analis Wall Street yang menawarkan target harga 12 bulan untuk ATAI dalam 3 bulan terakhir.
Tertinggi
Saat ini US$4,50
US$25,00 (+455,56%)
Rata-Rata
US$14,90 (+231,11%)
Terendah
US$10,00 (+122,22%)
Artikel berita
Dari berbagai sumber di seluruh web
Yahoo! Finance Canada
·
8 jam yang lalu
AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating
Yahoo Finance
·
19 jam yang lalu
Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)?
Profil
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Tentang AtaiBeckley Inc
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut